The MM120 ODT Phase 3 clinical development program also includes the Voyage study for GAD and the Emerge study for major depressive disorder (MDD). The U.S. Food and Drug Administration has granted ...

Antidepressants, such as Prozac, are already used to treat the condition but Canadian and Italian scientists set out to analyse new evidence of the drugs' effectiveness.

Learn the key differences between disease, disorder, and syndrome, helping to understand diagnosis, treatment, and the ...

A new Cochrane review confirms that antidepressants effectively reduce symptoms of generalized anxiety disorder (GAD) under trial conditions, although there is limited data on long-term usage.

Glutamatergic medications are linked to significant symptom improvement in obsessive-compulsive and related disorders, a new ...

A new Cochrane review confirms that antidepressants effectively reduce symptoms of generalized anxiety disorder (GAD) under ...

For adults with opioid use disorder (OUD) receiving buprenorphine, a mindfulness-based group is similar to a recovery support ...

Inc. stock despite strong Phase 2b data. Click for my updated look at MNMD stock and its market opportunities.

A study found that older adults with anxiety may have an increased risk of developing dementia—but this risk decreased once ...

Atai Life Sciences N.V. reported positive top-line phase 2a results of BPL-003 in treating Alcohol Use Disorder patients.

Why We Need Fast-Acting Anxiety Relief Now More Than Ever Anxiety isn’t just feeling nervous before a big event—it can be relentless, overwhelming, and even debilitating. Traditional treatments like ...

Weill Cornell Medicine investigators have identified in a preclinical model a specific brain circuit whose inhibition appears ...